PD L1 News and Research

RSS

Distinct plasma proteins linked to presence and course of COVID-19

In a study published in Viruses, researchers have examined the difference in protein levels in COVID-19 patients.

10 Dec 2021

New approach to enhance the therapeutic efficacy of liver cancer immunotherapy

In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.

7 Dec 2021

SPORE-funded Kidney Cancer Program at UT Southwestern reports wide array of tumor models to date

Funded by a Specialized Program of Research Excellence award from the National Cancer Institute (NCI), the Kidney Cancer Program at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center reports the largest and most diverse catalog of kidney cancer tumor models to date.

29 Nov 2021

Researchers develop model for early prediction of cancer patients' response to immunotherapy

Researchers have developed a model that could predict early on in treatment whether cancer patients will respond to immunotherapy, according to a report published today in eLife.

9 Nov 2021

Experts reveal improved survival for patients with two out of three types of advanced breast cancer

Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least five years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6).

7 Nov 2021

Deadly parasite could potentially be used to treat various types of cancers

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various types of tumors.

3 Nov 2021

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center.

2 Nov 2021

Two new studies show how to enhance effectiveness of cancer immunotherapy

Two new studies revealed that anti-PD-1 immunotherapy given before surgery was safe and effective for patients with oral-cavity squamous cell carcinoma (OCSCC) and identified potential molecular biomarkers in the blood and tumors of patients that would show how likely it is that someone would respond to immunotherapy.

30 Oct 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Black NSCLC patients receiving immunotherapy have lower risk of death than white counterparts

Non-Hispanic Black patients with non-small cell lung cancer (NSCLC) who were treated with immunotherapy had a lower risk of death than their non-Hispanic white counterparts treated with immunotherapy, according to results presented at the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held October 6-8, 2021.

6 Oct 2021

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

1 Oct 2021

Classic antidepressants show potential to enhance modern cancer treatments

Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term.

28 Sep 2021

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.

24 Sep 2021

Penn Medicine and Wistar secure $11.7 million SPORE grant for three melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Cancer Institute.

22 Sep 2021

Specially designed lipid nanoparticles overcome resistance to anti-tumor immunotherapy

A specially designed lipid nanoparticle could deliver immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy.

18 Sep 2021

Scientists identify new approach to overcome resistance to cancer immunotherapy

Hokkaido University scientists and colleagues in Japan have found a way that could help some patients overcome resistance to immunotherapy treatment for cancer. The approach, proven in mice experiments, was reported in the Journal for Immunotherapy of Cancer.

17 Sep 2021

Synthetic molecular code shows promise towards improving immunotherapy response of cancer patients

A synthetic molecular code shows promise towards improving the response of some cancer patients to immunotherapy treatments.

14 Sep 2021

Study identifies actionable genes and candidate drugs in biliary tract cancer using a knowledgebase

Oncotarget published "Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase" which reported that it is necessary to investigate actionable genes and candidate drugs using a sophisticated knowledgebase and characterize BTCs immunologically for evaluating the actionability of molecular and immune therapies.

31 Aug 2021

MSK researchers identify potential biomarker of response to checkpoint immunotherapy

In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of people with several types of cancer, including melanoma, lung cancer, bladder cancer, and many more.

25 Aug 2021

New PULSAR radiation-therapy strategy achieves better tumor control

Artificial intelligence, along with a $71-million expansion of Radiation Oncology services, is allowing UT Southwestern Medical Center cancer physicians to pioneer a new PULSAR radiation-therapy strategy that improves tumor control compared with traditional daily therapy.

From Elekta 20 Aug 2021